FDA Approves PROLENSA from Bausch + Lomb

The FDA has granted Bausch + Lomb approval for PROLENSA, its anti-inflammatory prescription eye drop for patients that have undergone cataract surgery.

The bromfenac ophthalmic solution, which will be offered in 1.6ml and 3ml bottles, is designed to reduce ocular inflammation and pain.

More Articles on Ophthalmology:
Arizona Aiello Eye Institute Expands Services to Foothills Location
LENSAR Laser System Earns FDA 510(k) Clearance
Devers Eye Institute Offers Corneal Crosslinking

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast